Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes by Bonnefoi, Herve et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III
study: pathological response after neoadjuvant chemotherapy
and clinical outcomes
Citation for published version:
Bonnefoi, H, MacGrogan, G, Poncet, C, Iggo, R, Pommeret, F, Grellety, T, Larsimont, D, Becette, V,
Kerdraon, O, Bibeau, F, Ghnassia, J-P, Picquenot, J-M, Thomas, J, Tille, J-C, Slaets, L, Bodmer, A, Bergh,
J & Cameron, D 2019, 'Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological
response after neoadjuvant chemotherapy and clinical outcomes', British Journal of Cancer.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
British Journal of Cancer
Publisher Rights Statement:
This is a pre-copyedited, author-produced version of an article accepted for publication in "British Journal of
Cancer" following peer review. The version of record "Molecular apocrine tumours in EORTC 10994/BIG 1-00
phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes." is available
online at: DOI: 10.1038/s41416-019-0420-y / https://www.nature.com/articles/s41416-019-0420-y
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Oct. 2019
 1 
 
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological 
response after neoadjuvant chemotherapy and clinical outcomes 
 
Running title: Molecular apocrine breast cancers  
 
Hervé Bonnefoi (1) 
Gaetan MacGrogan (2) 
Coralie Poncet (3) 
Richard Iggo (4) 
Fanny Pommeret (1) 
Thomas Grellety (1) 
Denis Larsimont (5) 
Véronique Bécette (6) 
Olivier Kerdraon (7) 
Frédéric Bibeau (8) 
Jean-Pierre Ghnassia (9) 
Jean-Michel Picquenot (10) 
Jeremy Thomas (11) 
Jean-Christophe Tille (12) 
Leen Slaets (3) 
Alexandre Bodmer (13, 14) 
Jonas Bergh (15, 16) 
David Cameron (17,18) 
and on behalf of the EORTC 10994/BIG 1-00 study investigators
 2 
Affiliations 
(1) Department of Medical Oncology, Institut Bergonié Unicancer, Univ. Bordeaux, INSERM 
U1218, INSERM CIC1401, Bordeaux, France 
(2) Department of BioPathology, Institut Bergonié Unicancer, INSERM U1218, Bordeaux, 
France 
(3) European Organisation for Research and Treatment of Cancer EORTC) Headquarters, 
Brussels, Belgium 
(4) Institut Bergonié Unicancer, INSERM U1218, Bordeaux, France 
(5) Department of Pathology, Institut Jules Bordet, Brussels, Belgium 
(6) Department of Pathology, Institut Curie - Hôpital René Huguenin, Saint-Cloud, France 
(7) Department of Pathology, Centre René Gauducheau, Institut de Cancérologie de l'Ouest, 
Nantes, France 
(8) Department of Pathology, Institut de Cancérologie de Montpellier (ICM), Montpellier, 
France 
(9) Department of Pathology, Centre Paul Strauss, Strasbourg, France 
(10) Department of Pathology, Centre Henri Becquerel, Rouen, France 
(11) Department of Pathology, Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, 
United Kingdom 
(12) Department of Pathologie, Hôpitaux Universitaires de Genève (HUG), Geneva, 
Switzerland 
(13) Swiss Group for Clinical Cancer Research (SAKK), Bern  
(14) Department of Oncology, Hôpitaux Universitaires de Genève (HUG), Geneva, Switzerland 
(15) Swedish Breast Cancer Group (SweBCG), Stockholm  
(16) Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden 
(17) Anglo-Celtic Cooperative Oncology Group (ACCOG), Edinburgh 
(18) Department of Medical Oncology, Edinburgh Cancer Centre, University of Edinburgh, 
Edinburgh, United Kingdom  
 
 3 
Corresponding author 
Prof Hervé Bonnefoi 
Department of Medical Oncology, Institut Bergonié Unicancer, Univ. Bordeaux, INSERM 
U1218, INSERM CIC1401, 229 Cours de l’Argonne, F-33000 Bordeaux, France.  
Email: h.bonnefoi@bordeaux.unicancer.fr 
Phone: +33 556 33 32 69 Fax: +33 556 33 33 30
 4 
Abstract  
Background: We explored, within EORTC10994 study, the outcomes for patients with 
molecular apocrine (MA) breast cancer, defined immunohistochemically (IHC) as androgen-
receptor (AR) positive, oestrogen (ER) and progesterone (PR) negative. We also assessed 
the concordance between IHC and gene expression arrays (GEA) in the identification of MA 
cancers. 
Methods: Centrally-assessed biopsies for AR, ER, PR, HER2 and Ki-67 by IHC were 
classified into 6 subtypes: MA, triple negative (TN) basal-like, luminal A, luminal B HER2-
negative, luminal B HER2-positive, and "other". The two main objectives were the pathological 
complete response (pCR) rates and survival outcomes in the overall MA subtype (and further 
divided by HER2 status) and the remaining 5 subtypes. 
Results: IHC subtyping was obtained in 846 eligible patients. Ninety-three (11%) tumours 
were classified as MA subtype. Both IHC and GEA data were available for 64 patients. In this 
subset, IHC concordance was 88.3% in identifying MA tumours compared to GEA. Within the 
MA subtype, pCR was observed in 33.3% (95%CI: 29.4-43.9) and the 5-year recurrence-free 
interval was 59.2% (95%CI: 48.2-68.6). Patients with MA and TN basal-like tumours have 
lower survival outcomes.  
Conclusions: Irrespective of their HER2 status, the prognosis for MA tumours remains poor 
and adjuvant trials evaluating anti-androgens should be considered.  
 
Key words 
Breast cancer, neoadjuvant chemotherapy, androgen receptor, molecular apocrine cancer, 
triple negative breast cancer 
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Introduction 
Several gene expression array (GEA) studies have identified a breast cancer subtype 
characterized by the expression of the androgen receptor (AR), absence of the oestrogen 
receptor α (ER), and expression of many genes that are expressed in ER-positive luminal 
tumours (Doane AS, 2006; Farmer et al, 2005; Guedj et al, 2012). We named these tumours 
"molecular apocrine" (MA) as they have an increased androgen signalling expression profile 
and some, but not all, morphological hallmarks of apocrine tumours (Farmer et al, 2005). In 
approximately two-thirds of the cases, these tumours are human epidermal growth factor 
receptor 2 (HER2) positive; the importance of this HER2-positive AR-driven group of tumours 
has been recently highlighted (Daemen & Manning, 2018). The remainder are HER2-negative 
and are part of the heterogeneous triple negative breast cancer (TNBC) group. 
  
In both HER2-positive and HER2-negative subgroups of MA tumours, prospective trials 
evaluating anti-androgens in patients with advanced breast cancer are ongoing. In these trials 
MA tumours are identified using an immunohistochemical (IHC) definition. In the HER2-
negative sub-group, three prospective clinical trials demonstrated anti-tumour efficacy with 
anti-androgen treatment (Bonnefoi et al, 2016; Gucalp et al, 2013; Traina et al, 2018) and with 
long-term responders (Grellety et al, 2018). In the HER2-positive sub-group, encouraging 
preliminary results have been reported from a Simon 2-stage phase two study (Krop et al, 
2016). These data have reinforced the interest in the MA subtype and the logical next step 
would be to evaluate these anti-androgen treatments in patients with MA early breast cancer, 
at least in the HER2-negative group.  
  
Before considering adjuvant studies, there is a need to better understand the frequency of the 
MA subtype and its natural history. Previously published EORTC 10994/ BIG 1-00 study 
(Bonnefoi et al, 2011) offered an excellent opportunity to explore the outcomes for patients 
with MA tumours compared to other subtypes using an IHC definition. MA tumours were 
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identified using the following definition: AR-positive and ER-, progesterone receptor (PR)-
negatives. Moreover, we categorized MA tumours into two sub-groups according to HER2 
status. This IHC definition is commonly used to identify MA subtype in prospective therapeutic 
clinical trials in advanced breast cancer (Bonnefoi et al, 2016; Gucalp et al, 2013; Traina et al, 
2018). Other subtypes were defined in a similar way to the St Gallen 2011 simplified 
classification (Goldhirsch et al, 2011) with the exception of the basal-like subtype, which was 
by definition, AR negative (quadruple negative) in this study.  
  
MA subtype was initially identified using GEA (Doane AS, 2006; Farmer et al, 2005; Guedj et 
al, 2012). For pragmatic reasons IHC is used to identify this subtype in prospective 
therapeutic trials. However the agreement between these two methods has never to our 
knowledge been assessed. Thus we determined in a subset of patients included in this sub-
study, the concordance of IHC compared to this GEA classification in the identification of MA 
tumours. We used a biologically-based GEA classification of breast cancer recently 
developed to identify MA tumours (Iggo, 2018).  
 
 
Materials and methods 
Study design, eligibility and treatment 
This was an unplanned analysis within the EORTC 10994/BIG 1-00 neoadjuvant phase III trial, 
in which 1856 patients were randomized in a 1:1 ratio between six cycles of fluorouracil, 
epirubicin, cyclophosphamide and a taxane-based regimen, docetaxel for three cycles 
followed by epirubicin+ docetaxel for three cycles, all administered prior to primary surgery as 
previously described (Bonnefoi et al, 2011). Two frozen biopsies from the primary tumour were 
mandatory for research purposes. Formalin fixed paraffin embedded (FFPE) biopsies were 
performed for diagnostic purposes. Eligible patients for the EORTC 10994/BIG 1-00 trial were 
women <71 years with histologically-proven invasive breast cancer suitable for neoadjuvant 
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chemotherapy, with any large operable or locally advanced/inflammatory breast cancer. At 
completion of chemotherapy, locoregional treatment was planned in accordance with the 
guidelines described in the protocol. Treatment was completed with hormonal therapy 
according to each centre’s policy. Patients with HER2-positive tumours were allowed to 
participate in adjuvant clinical trials assessing trastuzumab or to receive this treatment in the 
adjuvant setting once it became standard practice, but none received neoadjuvant 
trastuzumab. The trial was registered with ClinicalTrials.gov number NCT00017095 and 
approved by national and/or local ethics committees in all participating centres. Before 
registration, all patients signed an informed consent for the trial and for mandatory p53 gene 
assessment on tumour samples. In addition patients were asked to consent for optional 
biological research on their tumour samples. 
  
For the sub-study that is the subject of this report, a subgroup of the initial population of 1856 
patients was selected based on the following criteria: (i) patients eligible for the main EORTC 
10994/BIG 1-00 trial; (ii) patients who received at least one cycle of neo-adjuvant 
chemotherapy and who did not receive radiotherapy before surgery; (iii) patients who agreed 
to consent for optional biological research on their tumour samples; (iv) patients with sufficient 
tumour in their pre-treatment core biopsies and whose tumour subtype was identified based 
on the central analysis of their biopsies included in the ancillary tissue microarray (TMA) study.  
 
Histopathological assessment 
Histological type and grade were assessed locally by pathologists at each participating centre 
and the data collected on case report forms in the context of the EORTC 10994 trial. 
Pathological response was assessed by local pathologists after completion of the neoadjuvant 
chemotherapy. No central pathology review was performed either for histological type and 
grade at diagnosis or pathological response at surgery.  
 
Construction of tissue microarrays  
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Breast cancer FFPE core biopsies taken at diagnosis before neoadjuvant chemotherapy were 
retrospectively collected and sent to Institut Bergonié by different participating centres. All core 
biopsies were reviewed on H and E-stained sections, and representative tumour areas were 
selected for TMA construction. For each case, three 0.6 mm-diameter tumour cores were used. 
The TMA was constructed using a tissue micro-arrayer (Alphelys France). Evaluation of the 
entire section was performed by a board certified pathologist (GMG). 
 
Immunohistochemical and dual detection in situ hybridisation methods and 
interpretation 
Tumour phenotype concerning AR, ER, PR, HER2 status, and proliferation status (Ki-67) were 
defined on TMA. AR was scored as positive if ≥10% of tumour cell nuclei showed a positive 
signal. This is the commonly used cut-off (Bonnefoi et al, 2016; Gucalp et al, 2013; Traina et 
al, 2018). ER and PR were scored negative if <1% of tumour cells were positive. For Ki-67, 
results were given by % of positive cells. The threshold used to define high Ki-67 expression 
was ≥14% (Cheang et al, 2009). For HER2, results were given by % of positive cells and 
intensity of staining. Final HER2 status was scored according to the ASCO/CAP 
recommendations (Wolff et al, 2013). An IHC3+ score was considered positive. An IHC2+ 
score was considered equivocal. It was then retested by silver in situ hybridisation (SISH). 
Cases with ≥6 HER2 copies per cell nucleus were considered positive. Details for IHC staining 
of ER, PR, HER2, Ki67 and AR are provided in the supplementary table 1. 
 
Simplified breast cancer molecular subtypes classification 
Tumours were classified into 6 subtypes: MA, triple negative basal-like (as named in the first 
gene expression arrays classification) (Perou et al, 2000), luminal A, luminal B HER2-negative, 
luminal B HER2-positive, and non-luminal non-MA HER2-positive. This classification is 
detailed in table 1. The MA subtype was further divided in two subgroups according to HER2 
status: positive or negative. The luminal group (ER and/or PR positive, any HER2 status, any 
Ki67) was further divided in two subgroups according to AR status: positive or negative.   
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TP53 status  
TP53 status from frozen biopsies was assessed using a yeast functional test as previously 
described (Flaman et al, 1995; Waridel et al, 1997). 
 
Gene expression array analysis 
Microarray data from our previous studies (Farmer et al, 2009; Farmer et al, 2005) was 
downloaded from the NCBI GEO database using accession numbers GSE1561 and GSE6861. 
A biology-based classification of breast cancer was developed using a mammary lineage 
model (supplementary figure 1) (Iggo, 2018). The first step in the classification splits tumours 
into hormone sensing tumours (10 transcripts including ESR1, AR, FOXA1) and secretory cell 
tumours (9 transcripts including ELF5, FOXC1, KLF5). The second step splits hormone 
sensing tumours into classic ER+ luminal tumours and molecular apocrine tumours. To 
separate luminal from molecular apocrine tumours, 30 genes were selected based on 
correlation with ESR1 expression, half showing positive (luminal) and half negative (molecular 
apocrine) correlation. Using these 30 genes luminal and apocrine scores were created. This 
classification uses a total of 49 preselected transcripts (supplementary figure 1). Of note 
ERBB2 is not in the list. The tumours were assigned to luminal, molecular apocrine and basal 
(LAB) classes as described (Iggo, 2018). The LAB classification includes a fourth category, 
"unknown" or "non-interpretable", for tumours that are too close to the thresholds separating 
classes to be assigned any particular class confidently. Full details of this classification can be 
found in the publication (Iggo, 2018). 
 
Objectives and end-points definitions 
The two main objectives were to describe the pathological complete response (pCR) rates and 
to report the survival outcome measures, recurrence-free interval (RFI), distant recurrence-
free interval (DRFI) and overall survival (OS): (i) in the MA subtype (in the overall MA 
population and in the two subgroups according to HER2 status); (ii) in the remaining 5 
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subtypes, (iii) within the luminal group (3 subtypes: luminal A, luminal B HER2 negative, 
luminal B HER2 positive), in the two subgroups according to AR status (any HER2 and Ki67 
status).  As an additional aim we also assessed in a subset of patients the agreement of IHC 
to identify MA cancers compared to the gold standard GEA. 
  
pCR was defined as no evidence of residual invasive cancer (or very few scattered tumour 
cells left) with or without residual ductal carcinoma in situ (DCIS) and negative axillary lymph 
nodes (ypT0/is ypN0).  Patients whose tumour progressed on neoadjuvant chemotherapy and 
patients who did not undergo surgery or with missing information on the surgical pathology 
report were considered as having "no pCR".  
 
The survival endpoints were defined according to the standardised definitions for efficacy end-
points (STEEP) system (Hudis et al, 2007). RFI was measured as time from randomization to 
progression on chemotherapy, ipsilateral invasive breast (local) recurrence, regional 
recurrence (chest wall and regional nodes: axillary, internal mammary, infraclavicular, and 
supraclavicular nodes), distant recurrence or death due to breast cancer and/or treatment 
toxicity, whichever came first. DRFI was calculated as the time from randomization to distant 
recurrence or death due to breast cancer and/or treatment toxicity, whichever came first. OS 
was calculated as the time from randomization to death due to any cause. In the EORTC 
10994/BIG 1-00 trial, both first locoregional recurrence and first distant metastasis were 
registered. Events diagnosed within two months were considered as simultaneous and we 
chose to declare the site of first event as the one with the worst prognosis. Patients who did 
not present with any of the events mentioned above during their follow-up were censored at 
the time of their last follow-up. Contralateral breast cancer and second primary invasive cancer 
(non-breast) were not considered as primary events. 
 
Statistical analysis 
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A statistical analysis plan was prospectively defined. All the statistical analyses were 
performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). 
pCR analysis 
Logistic regression model was used to estimate the effect of subtype on the odds of having a 
pCR. The associated exact 95% Clopper-Pearson confidence interval and p-value based on 
the Wald method were also presented. Three logistic models were conducted: (i) comparing 
the six simplified subtypes using the luminal A as reference group, (ii) within the MA subtype, 
comparing HER2 positive to HER2 negative subgroups, (iii) within the luminal group (3 
subtypes as mentioned before), comparing AR-positive to AR-negative subgroups.  
Survival outcomes 
Time to event end-points were analysed per Kaplan Meier method reporting 5-year estimate 
and corresponding Kaplan-Meier curve. P-values were based on the logrank test. Hazard 
ratios were estimated from a Cox proportional hazards model and the corresponding 95% 
confidence intervals (CI) (Wald method) were added. 
Concordance between IHC and GEA subtype classification 
In the subset of patients with both subtype classifications based on IHC or GEA methods, the 
proportion of concordant subtype classification and Kappa agreement coefficient as well as 
their 95% confidence intervals were estimated. 
 
Results 
Of the 1856 patients originally randomized, core biopsies of 1092 eligible patients were 
centralized in Bordeaux and available for the TMA construct. A total of 846 patients with a 
tumour classified in one of the 6 IHC-based subtypes (table 1) based on this TMA were 
included in this sub-study. The reasons for ineligibility are shown in the Consort diagram 
(supplementary figure 2). Baseline characteristics and treatment of patients included in this 
analysis (eligible) and those excluded are presented on supplementary table 2 (significant p-
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values below 0.05 are indicated). The median follow-up of the patients included in this sub-
study was 56 months from the date of randomization. We will first describe the MA population. 
 
Molecular apocrine tumours 
A total of 93/846 (11.0%) eligible tumours were classified in the MA subtype. Baseline 
characteristics and treatment are reported in supplementary table 4. Median age was 54.1 
years. Ki67 was high in 81.5% (75/92) and TP53 status was mutated in 72.1% (49/68) patients. 
Approximately one-third of MA tumours were HER2-negative (32/92) and two thirds were 
HER2-positive (59/92) and one case was equivocal. MA HER2-negative tumours represented 
25.4% of all triple negative breast cancers (32/126). Patient and tumour characteristics were 
compared between HER2-positive and HER2-negative groups. MA HER2-positive tumours 
presented more frequently with a high Ki67. All the other characteristics were similar between 
the two groups except nodal status and Ki67.  
 
A pCR was observed in 31 of 93 (33.3%, [95%CI: 23.9-43.9]) patients with MA tumours (table 
2). pCR rates were not significantly different between HER2-negative and positive subgroups 
(Odds ratio HER2-positive versus HER2-negative 1.31 ([95% CI: 0.51-3.36]; p =0.57). 
  
The RFI, DRFI and OS curves are shown in figure 1 and supplementary figures 3 and 4. The 
5-year estimate of RFI rate was 59.2% (95%CI: 48.2-68.6) (figure 1 and supplementary table 
3). Within the MA subtype, survival outcomes measures were not statistically different between 
HER2-positive and negative sub-groups (figure 1 and supplementary table 5). Approximately 
one-third of first events in MA cancers were loco-regional recurrences (supplementary table 
6). Patterns of distant relapses are reported in supplementary table 7.  
 
Other molecular subtypes and comparison with molecular apocrine subtype 
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Baseline characteristics and treatment are reported in supplementary table 9. Patients with 
MA tumours when compared with other molecular subtypes were older and more often 
postmenopausal. 
  
pCR rates differed significantly (p<0.001) across intrinsic subtypes, with the lowest rate for 
luminal A (8.7%, [95%CI: 5.3-13.2]) and the highest rates for MA and triple negative basal-like 
(33.3%, [95%CI: 23.9-43.9] and 34.0%, [95%CI: 24.6-44.5], respectively) (table 2). The pCR 
rate of HER2-positive non-luminal and non-MA tumours was high (42.9%, [95%CI: 10.0-81.6]) 
but the number of patients in this group is very small. 
 
Patients with MA and triple negative basal-like tumours showed the lowest 5-year RFI, DRFI 
and OS estimates (figure 2, supplementary table 3, supplementary figures 5 and 6). 
  
Within luminal subtypes, 8.6% (luminal A) to 18.2% (luminal B HER2-negative) experienced 
loco-regional recurrence as first event contributing to RFI. In non-luminal subtypes including 
MA tumours, one-third of patients experienced loco-regional recurrence as first event 
contributing to RFI (supplementary table 6).  
 
Patterns of distant relapses by simplified breast cancer subtypes are reported in 
supplementary table 7. Compared with patients with luminal tumours, patients with MA 
tumours presented more often with visceral metastasis (p=0.0343) and less often with bone 
metastasis (p=0.0006) (supplementary table 8). 
 
Analysis of the ER and/or PR positive group by AR status 
Within the luminal group, 93.7% (599/639) were AR-positive. pCR rates were not statistically 
different by AR status (Odds ratio 0.62, [95%CI: 0.27-1.39]; p=0.242) (supplementary table 
10). RFI, DRFI and OS were not statistically different by AR status (supplementary table 11).  
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Concordance of immunohistochemistry with gene expression to identify molecular 
apocrine cancers 
We compared the gene expression-based LAB classification (Iggo, 2018) with IHC 
classification in a subset of 64 patients for whom GEA and IHC data were available. Note that 
the selection of cases for GEA was not random: it was enriched for ER-negative tumours. By 
definition the LAB classification splits tumours into only three groups: luminal, MA and basal-
like (table 1). Hence, to compare it to IHC classification we assigned cases to three IHC groups 
(luminal, MA and basal-like) based on IHC for ER, PR and AR. In four patients the gene 
expression values were too close to the thresholds for the tumours to be assigned confidently 
to any particular group, leaving 60 samples for comparison with the IHC data. The 
concordance was 88.3% (95%CI: 80.2-96.5).  The Kappa agreement coefficient between IHC 
and GEA methods to identify the LAB MA subtype was 0.82 (95%CI: 0.694-0.945) (table 3).  
HER2 is not used in the LAB classification because it is commonly expressed by both luminal 
and MA tumours (our hypothesis is that HER2 promotes apocrine metaplasia of luminal cells 
leading to a high frequency of HER2 amplification in the MA group). To illustrate the potential 
limitations of using HER2 to identify MA tumours we plotted HER2 against ESR1 in figure 3A 
(the tumours are labelled according to the LAB classification in three molecular groups). 
Tumours expressing high levels of HER2 were indeed classified as MA but several tumours 
with high levels of HER2 were luminal (upper right quadrant) or even basal-like, and one MA 
tumour expressed a low level of HER2. Figure 3B shows the distribution of AR and ESR1 
expression in the three molecular groups. The tumours fall into the three expected groups: MA 
tumours (AR high and ESR1 low) in the upper left quadrant, basal-like tumours (AR low and 
ESR1 low) in the lower left quadrant, and luminal tumours (AR high and ESR1 high) in the 
upper right quadrant.  
Supplementary figures 7 and 8 highlight the seven discordant cases between the IHC and 
GEA classifications. Five discordant cases lie close to the thresholds separating the tumour 
types and can readily be explained by slightly differing placement of the thresholds by the two 
approaches. For example, tumours 250 and 337 are classified as MA by gene expression but 
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luminal by IHC; they express AR well but they also express ESR1 at a level almost exactly at 
the cut-off separating luminal from MA tumours (supplementary figure 8). The two remaining 
discordant cases are outliers (tumours 335 and 856). In these two cases possible explanations 
for the discordance are, post-transcriptional modifications, tumour heterogeneity or even a 
sample labelling issue.  
In summary, the overall agreement between classification by IHC and gene expression was 
good, with the disagreements concentrated near the thresholds. 
Moreover we compared LAB classification and a simplified PAM50 classification (Parker et 
al, 2009). We used 43 genes out of the 50 genes which constitute PAM50 successfully 
mapped to the Affymetrix dataset (7 genes were not present on the U133A chip). We 
excluded from the comparison tumours which were incomparable (classified as Normal by 
PAM or unknown by LAB) leaving 59 tumours to compare. There was a perfect agreement 
between the two classifications for the basal tumours. Of note 89.3% (25/28) of those 
classified as luminal by PAM were classified as luminal by LAB; three luminal tumours by 
PAM were MA by LAB. Moreover 78.6% (11/14) of those classified as molecular apocrine by 
LAB were classified as HER2-enriched by PAM (supplementary table 12).  
 
Discussion 
With a total of 93 MA cancer patients, this is the largest series from a prospective neoadjuvant 
trial assessing clinicopathological characteristics, frequency, chemosensitivity and prognosis 
of this subtype.  
 
In this series, patients diagnosed with MA were older (median age 54.1) and were more often 
postmenopausal (62.4%) compared to other subtypes. One-third of the first relapses were 
locoregional. This proportion is similar to that observed in triple negative basal-like subtype. 
Two-thirds of MA tumours were HER2-positive and the remainder, HER2-negative. TP53 
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mutation rate was high (72.1%) and was similar to the one observed in triple negative basal-
like cancers (73.3%).  
 
Regarding frequency, 11% of cancers were classified in the MA subtype. Within the TNBC 
group, approximately one-quarter were MA (32/126). This information is potentially important 
when estimating the feasibility of a prospective trial in this molecular subtype in early breast 
cancer particularly in the HER2 negative subgroup where no targeted therapy can be offered. 
In the literature, based on IHC, the frequency of MA tumours in the TNBC group ranges from 
21.6% (24/111) in the GBG Gepartrio sub-study (Loibl et al, 2011) to 35.9% (122/339) in the 
Nurses' Health study (Collins et al, 2011). Based on GEA, using the TNBCType classification, 
the frequency of MA tumours is 11.1% (65/587) in a first analysis of 21 publicly available breast 
cancer GEA data sets performed by the Vanderbilt University group (Lehmann et al, 2011). In 
a second Vanderbilt University analysis, the authors simplified their classification from six into 
four subtypes (TNBCtype-4). Using this refined TNBCtype-4 classification, the frequency is 
16% (50/316) in a second analysis performed by this group combining 5 publicly available GEA 
data sets of patients treated with neoadjuvant chemotherapy (Lehmann et al, 2016). Using a 
different classification algorithm, the frequency of MA is 17.7% (35/198) in a series of tumours 
collected from U.S. and European sites, with IHC triple negative status centrally reviewed and 
GEA analysed in Houston (Burstein et al, 2015).  
 
The difference in the frequency of AR-positive TNBCs, whether IHC or GEA was used, is 
difficult to explain given that there is 88.3% concordance between IHC and GEA to identify MA 
subtype in our EORTC series. We believe that this high concordance rate validates the IHC 
approach taken in this study. Although not perfect, IHC has the advantage of being inexpensive 
and routinely available in diagnostic histopathology departments. In addition, IHC is commonly 
used to identify MA cancers in therapeutic trials assessing anti-androgen treatments from 
which a significant proportion of patients benefited (Bonnefoi et al, 2016; Gucalp et al, 2013; 
Traina et al, 2018). We suspect, however, that real progress in the identification of these 
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tumours will come not from analysis of arbitrary signatures or IHC profiles but rather from a 
deeper understanding of the underlying biological entity so we can devise tests that identify 
that entity on the basis of its essential properties. It was for this reason that we developed the 
LAB classification (Iggo 2018). 
 
There are few data reported in the literature regarding chemosensitivity of MA tumours in 
particular, in the HER2-negative subgroup. In the GBG series, the authors used IHC to identify 
MA tumours. In the TNBC group (n=111), the pCR rates of AR-positive (n=24) and negative 
(n=87) tumours were similar, 29.2% and 33.3%, respectively (Loibl et al, 2011). In our series, 
within the TNBC group (n=126), the pCR rates of AR-positive (n=32) and negative (n=94) 
tumours were also similar. In the first Vanderbilt University analysis of TNBC, a total of 42 
patients included in 2 trials received neoadjuvant chemotherapy (Lehmann et al, 2011). The 
pCR rates were 14.3% (1/7) and 63.2% (12/19) in MA named luminal AR and basal-like 
subtypes, respectively (Lehmann et al, 2011). The MD Anderson Cancer Center (MDACC) 
group used a similar approach with GEA in a series of 130 evaluable patients with TNBC 
treated with neoadjuvant chemotherapy (Masuda et al, 2013). In luminal AR, basal-like 1 and 
basal-like 2 subtypes, the pCR rates were 10% (2/20), 52.4% (11/21) and 0% (0/8), 
respectively. In the second Vanderbilt University analysis, the authors used their simplified 
TNBCtype-4 classification and assessed the pCR rates in each subtype using data from 4 
publicly available GEA data sets (including the MDACC cohort) corresponding to a total of 306 
patients with TNBC (Lehmann et al, 2016). In this publication the pCR rate in the luminal AR 
was 29% (15/52) which is similar to the results observed in IHC series. It is difficult to explain 
these apparently different results in pCR rates observed whether IHC or GEA with TNBCtype 
or GEA with TNBCtype-4 classifications were used to identify MA tumours. Our interpretation 
is that, as shown in the LAB classification (Iggo, 2018), it is easy to separate basal-like from 
luminal and MA tumours by gene expression but far more difficult to differentiate luminal and 
MA tumours. Hence, a possible explanation for the divergent results in pCR rates is that, when 
using the initial TNBCtype classification tool in the Vanderbilt University and MD Anderson 
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studies (Lehmann et al, 2011; Masuda et al, 2013) a low pCR rate in the LAR group was 
observed because they may have included within this group some classic ER-positive luminal 
tumours, a subgroup known to have lower pCR rates. By their own admission, the Vanderbilt 
group acknowledge that they included from 55 to 82% of luminal A or B tumours (identified 
using the published intrinsic 306-gene set or the PAM50) in the LAR group (Lehmann et al, 
2011; Lehmann et al, 2016). 
 
In our series, patients with MA and triple negative basal-like tumours had the worst outcome. 
Although the distribution of recurrences during the first 3 years was very similar in the 2 groups, 
it becomes different after 3 years. In the triple negative basal-like group (n=94) a plateau was 
observed but not in the MA group (n=93) (figure 2). This plateau is a classic observation in 
basal-like series. For example, in a French study using GEA, the authors applied their 
molecular subtype classifier model to a large Affymetrix validation set comprising 2291 breast 
cancers. On the metastasis-free survival curves a plateau was  observed in the basal-like 
group (n=264) but not in the MA group (n=146). More than 40% of patients with MA tumours 
relapsed within 5 years and survival outcomes were not statistically different between HER2-
negative and positive sub-groups. However a numerical difference was observed for patients 
with MA HER2-positive tumours. This difference could be explained by the fact that only 1/3 of 
patients received adjuvant trastuzumab (EORTC10994/BIG 1-00 accrual period extended from 
April 2001 to November 2006; Herceptin became standard practice at the end of 2005 which 
explains why only 1/3 of patients received this treatment). As far as MA HER2-negative 
tumours are concerned, the risk of relapse at 5 years in the EORTC study was more than one-
third (34.5%). In the two Vanderbilt publications, using GEA based classifications for TNBCs, 
the risk of relapse at 5 years of MA cancers was 50% in both series of 62 and 50 MA tumours 
(Lehmann et al, 2011; Lehmann et al, 2016).  
 
Our study has some strengths and limitations. This is the largest series from a prospective trial 
assessing the frequency and the prognosis of MA tumours, in particular, in TNBCs. The main 
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weakness is that only 45.6% of patients included in EORTC 10994 study were included in this 
sub-study. In EORTC study two frozen biopsies were mandatory but we did not plan to 
prospectively collect FFPE blocks prior to neoadjuvant chemotherapy. Hence, these samples 
were collected retrospectively. However, the characteristics of patients included in this sub-
study and those who were excluded were similar (supplementary table 2). In addition there 
was no central assessment of pathological response. Lastly we did not use a transcriptomic 
signature to identify MA tumours and other subtypes. However, as mentioned before, both IHC 
and GEA methods have high concordance in the identification of MA tumours (88.3%).  
 
In conclusion, this study demonstrates that the prognosis of MA breast cancers is very poor 
despite their acceptable rate of pCR after neoadjuvant chemotherapy. Moreover the MA 
subtype is frequent, representing approximately 11% of all breast cancers and 25% within the 
TNBC group. This specific molecular subtype should be considered as an unmet need 
particularly in the HER2 negative subgroup where no targeted therapy can be offered. In the 
advanced setting, three clinical trials in patients with AR-positive TNBCs have demonstrated 
efficacy of anti-androgen treatments (Bonnefoi et al, 2016; Gucalp et al, 2013; Traina et al, 
2018). Based on the data reported in these publications anti-androgen treatments should be 
evaluated in the adjuvant setting in patients with AR-positive TNBCs. 
 
Additional information 
Ethics approval and consent to participate 
The trial was registered with ClinicalTrials.gov number NCT00017095 and approved by 
national and/or local ethics committees in all participating centres. Before registration, all 
patients signed an informed consent for the trial and for mandatory p53 gene assessment on 
tumour samples. In addition patients were asked to consent for optional biological research on 
their tumour samples. The study was performed in accordance with the Declaration of Helsinki. 
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Figures titles and legends 
 
Figure 1. Recurrence-free interval in the molecular apocrine subtype (any HER2 status, HER2 
positive and HER2 negative subgroups) 
 
Abbreviations: 
HR: hazard ratio; CI: confidence interval; MA: molecular apocrine; HER2-: human epidermal 
growth factor receptor 2 negative; HER2+: human epidermal growth factor receptor 2 
positive. 
 
 
Figure 2. Recurrence-free interval in the six subtypes 
 
Abbreviations: 
HR: hazard ratio; CI: confidence interval; lum A: luminal A; lum B: luminal B; HER2-: human 
epidermal growth factor receptor 2 negative; HER2+: human epidermal growth factor 
receptor 2 positive; MA: molecular apocrine; TN: triple negative. 
 
 
Figure 3. HER2, AR and ESR1 gene expression of individual tumours labelled by LAB 
class. A, HER2 and ESR1; B, AR and ESR1.  
 
Legend: 
The points are coloured according to the LAB classification. The gene expression units are 
arbitrary Affymetrix signal intensities after normalisation with the rma algorithm. 
 
Abbreviations: 
HER2: human epidermal growth factor receptor 2; AR: androgen receptor; ESR1: estrogen 
receptor 1; L: luminal; B: basal; MA: molecular apocrine.  
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Table 1. Simplified breast cancer molecular subtypes classifications (including the molecular apocrine subtype) 
Classification in 6 IHC 
subtypes 
Classification in 3 IHC 
subtypes for the 
comparison to GEA 
AR(1) ER/PR(2) HER2(3) Ki67(4) 
MA MA Positive Both negative Any Any 
Luminal A Luminal Any ER and/or PR positive Negative Low 
Luminal B HER2-negative  Any ER and/or PR positive Negative High 
Luminal B HER2-positive Any ER and/or PR positive Positive Any 
Triple negative basal-like 
 
Basal-like 
Negative Both negative Negative Any 
Non-luminal and non-MA 
HER2-positive 
Negative Both negative Positive Any 
Abbreviations: 
IHC: immunohistochemical; GEA: gene expression array; AR: androgen receptor; ER: oestrogen receptor; PR: progesterone receptor; HER2: human epidermal growth receptor 2; MA: 
molecular apocrine-like subtype. 
Legend: 
(1) AR positive ≥10%; 
(2) ER and PR negative <1%; 
(3) HER2 positive: immunohistochemistry (IHC) 3+ or IHC2+ and Dual Detection In Situ Hybridisation (DDISH); 
(4) Ki67 high ≥ 14%. 
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Table 2. pCR rates by simplified breast cancer molecular subtype 
 
 
Patients 
(N=846) 
 
 
No pCR 
(%) 
No data 
on residual 
tumoura 
(%) 
 
 
pCR 
(%) [95%CI] 
 
 
Odds ratio 
(95% CI) 
MA      
Any HER2-statusb 93 58 (62.4) 4 (4.3) 31 (33.3) [23.9, 43.9] 5.26 (2.78, 9.96) 
HER2-negative 32 21 (65.6) 2 (6.3) 9 (28.1)  
HER2-positive 59 37 (62.7) 2 (3.5) 20 (33.9)  
Triple negative basal-like            94 55 (58.5) 7 (7.4) 32 (34.0) [24.6, 44.5] 5.43 (2.88, 10.25) 
Luminal A                219 199 (90.9) 1 (0.5) 19 (8.4) [5.3, 13.2] 1.00 
Luminal B HER2-negative          323 279 (86.4) 3 (0.9) 41 (12.7) [9.2, 16.8] 1.53 (0.86, 2.72) 
Luminal B HER2+          Luminal B HER2-positive          110 77 (70.0) 3 (2.7) 30 (27.3) [19.2, 36.6] 3.95 (2.10, 7.41) 
Non-luminal and non-MA 
HER2-positive 
7 4 (57.1) 0 (0.0) 3 (42.9) [10.0, 81.6] 7.89 (1.64, 37.91) 
P-valuec     <0.001 
Legend: 
a No surgery performed (progression on neoadjuvant chemotherapy); considered as No pCR in the logistic regression model 
b Two patients with equivocal or missing HER2, not included in the subgroups by HER2-status  
c P value for Wald test of a difference between the 6 subtypes using a logistic regression model.  
 
Abbreviations: 
MA: molecular apocrine; pCR: pathological complete response; CI: confidence interval; HER2: human epidermal growth factor receptor 2. 
 27 
 
Table 3.  Molecular subtypes identified by gene expression array and 
immunohistochemistry for oestrogen, progesterone and androgen receptors 
 
GEA classification 
Total 
(N=60) 
Luminal 
(N=25) 
MA 
(N=14) 
Basal-like 
(N=21) 
 N (%) N (%) N (%) N (%) 
IHC classification               
 Luminal  (*)                  23 (38.3)                                                                                         2 (3.3)                         2 (3.3)                          27 (45.0)                       
 MA (**)                1 (1.7)                                                                                          12 (20.0)                      1 (1.7)                                                       14 (23.3)                       
 Basal-like (***)          1 (1.7)                                                                                          0 (0.0)                                                18 (30.0)                      19 (31.7)                                                                   
Abbreviations: 
GEA: gene expression array; 
IHC: immunohistochemistry; 
MA: molecular apocrine 
Legend: 
(*) ER-positive and/or PR-positive 
(**) AR-positive, ER- and PR-negatives 
(***) ER-, PR- and AR-negatives 
 
